All In Biotech

Drug Trial Radar · NCT01581593

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).

Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

45

Actual

Start

Nov 12, 2012

Primary completion

Aug 27, 2014

Study completion Aug 27, 2014

Sponsor

Lead sponsor
Kedrion S.p.A.Industry
Sponsor type
Industry
First posted
Apr 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Kedrion IVIG 10% (an immunoglobulin solution) is effective in treating Primary Immunodeficiency (PID).

Conditions

  • Primary Immunodeficiency
  • Agammaglobulinemia
  • Hypogammaglobulinemia
  • Antibody Deficiency

Interventions

  • Kedrion IVIG 10%Biological

    Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Acute, Serious Bacterial Infections in the Total ITT Population.Time frame: 13 months

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Allergy Associates of the Palm Beaches

    North Palm Beach, Florida

  • Family Allergy & Asthma Center, PC

    Atlanta, Georgia

  • Rush University

    Chicago, Illinois

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Midwest Immunology Clinic

    Plymouth, Minnesota

  • AAIR Research Center

    Rochester, New York

  • Optimed Research, LTD

    Columbus, Ohio

  • Dallas Allergy Immunology Research

    Dallas, Texas

  • AARA Research Center

    Dallas, Texas

  • Virginia Commonwealth University Health Systems

    Richmond, Virginia

  • Marycliff Allergy Specialists

    Spokane, Washington

  • Gordon Sussman Clinical Research Inc.

    Toronto, Ontario, Canada

  • Pediatric & Adult Allergy & Clinical Immunology

    Toronto, Ontario, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.